 rais led strength life scienc water qualiti howev
dental disappoint undercut manag optim
posit inflect final hand dental spin
come soon enough take restructur action
make increment invest busi risk-reward look
balanc us
solid beat rais dental woe distract strong result across
core portfolio report cash ep beat vs expect
organ growth led life scienc water qualiti
thank upsid compani boost guidanc
midpoint set in-lin guidanc said given recent
announc plan spin dental sale independ
compani understand lot scrutini
segment disappoint organ declin quarter
exacerb fact manag optimist forecast
last quarter dental final turn corner would stabil
low-single-digit growth clearli still much work
done turn around busi goe sharehold hand
shortfal like one biggest driver stock bp
under-perform vs peer concern horizon
includ worsen fx tariff/trad war angst tough y/i comp
believ capabl manag headwind
rais cash ep high-end
guidanc price target
biggest surpris dental slip back organ declin undercut
hope posit inflect briefli surfac organ
growth dental regress declin due
north american distribut channel destock declin europ
japan though manag encourag north american sell-
data investor like treat show-m stori rather
pin hope near-term posit inflect
strength qualiti led double-digit
hach high-single-digit trojan manag note trojan
gain market share north america municip treatment may
come expens player space xylem wedeco
busi china also remain growth mode water test/analyt
valuat midpoint rel rang trade
premium peer adjust ep cash ep vs target
rang pt assum trade premium
valu usd unless otherwis note
price prior trade day market close estimate unless otherwis note
best-in-class multi-industri name metric
hold much-covet posit among higher
qualiti prime coverag accord
sector-best consecut year
know-how rever danah busi system
posit includ recur revenu market
leadership across portfolio
spin dental independ publicli trade
compani announc plan spin
dental segment mix stand-alone publicli
trade compani tax-fre transact target
strateg rational dental flexibl
organ invest abl place
bigger spotlight standout portfolionam
nobel biocar recal argument behind
danah success spin-off part
spin manag expect recogn modest dis-
synergi annual basi
balanc sheet fulli reload comfort return
larger deal size keep pipelin
contain million small bolt-on
recent disclos becom
comfort return larger multi-billion dollar deal
size vein billion cepheid acquisit
even deploy billion acquisit
estim still anoth billion
firepow could feasibl deploy next
month suggest healthi level balanc sheet capacity/
option deal-mak medium term
given expens price-tag below-benchmark
expect return major integr stumbl pall
cepheid would damag faith investor
 disciplin also enhanc scrutini
dental segment turnaround given
process spun independ publicli trade
compani
bloomberg capit market estim upside/downside/target
follow spin believ
re-rat target rel price-to-earnings rang given
compani divest cyclic legaci industri
busi assum trade high-
end rang due strong outlook investor
enthusiasm pend dental spin potenti
 premium target group
multipl price-to-earnings adjust ep
cash ep estim impli valuat
support sector perform rate
market enter risk-off environ danah
deliv upsid synergies/accret target
stronger dental perform believ stock
may abl re-rat beyond high-end rel
rang premium target group multipl
adjust ep also see potenti
upsid adjust ep reach level includ
acceler organ growth end market improv
carri execut risk misstep
 integr dental turnaround could weigh
stock addit high-qual defens name
would lag market enter prolong risk-on
environ favor cyclic higher-beta stock could
see price-to-earnings contract premium peer
near low-end target rel rang also
risk end market slowdown result adjust
ep closer valuat
takeaway result
revenu high-growth
market double-
digit led china
north america
western europ
report cash ep beat estim consensu guidanc
report cash ep ahead estim
consensu guidanc rang beat driven entir
upsid life scienc water qualiti platform organ revenu growth
outpac forecast manag guidanc sequenti deceler
led growth life scienc environment appli solut
diagnost said disappoint unexpect
organ declin dental undercut manag hope voic last quarter
segment final turn corner would stabil low-single-digit growth
total oper margin expand bp y/i ahead estim
impli decent increment includ bp margin drag
translat transact fx headwind overal oper line came ahead
estim consist life scienc environment appli solut
off-set diagnost dental higher corpor expens below-
the-lin item mostli line estim though amort add-back
lower anticip final free cash flow convers quarter fell
histor convers averag attribut
time cash tax payment ytd manag expect normal
lower cash tax payment vs
capit market compani report note organ revenu growth estim sector actual
boost cash ep guidanc rang midpoint driven mostli
beat rais full-year cash ep guidanc
roughli midpoint new midpoint slightli consensu
time releas addit initi cash ep guidanc captur
estim consensu high-end would expect estim
natur gravit toward believ full-year boost
larg attribut upsid organ revenu compani forecast
roughli growth would impli full-year growth consist
prior forecast mid-single-digit expect partli off-set worsen
foreign exchang trend especi among emerg market currenc drive
million revenu headwind ep headwind furthermor escal
trade friction us china expect produc roughli
million cost inflat headwind per quarter across entir portfolio
manag prior forecast million compani still aim off-set increment
drag four-prong strategi price increas chang suppli chain
organ growthshad area multi-industri sector averagenot restatedfor spin electr equip multi-industri
modifi global manufactur locat seek exempt certain
busi product tariff duti
rais cash ep estim high-end guidanc
increas attribut ep beat vs estim
ep estim unchang sit high-end new
guidanc rang organ revenu growth estim
full year line guidanc
exhibit danah earn guidanc vs estim consensu
life scienc life scienc surpris upsid quarter impress
organ growth bp core margin expans manag highlight
segment ninth consecut quarter bp core margin improv beckman
life scienc saw high-single-digit organ growth posit result across major
product line geographi thank new product launch biolog genom
drive market share gain sciex deliv high-single-digit organ growth thank
pharma food test end market north america china leica microsystem
high-single-digit driven momentum recent product launch notabl pall deliv
double-digit organ growth led single-us technolog mid-teen industri
vertic three year sinc busi acquir pall achiev
million annual cost save nice track toward five-year target
million final recent acquisit deliv mid-teen revenu growth
help db tool sale funnel manag
dental sale primari disappoint dental segment slip
back organ revenu declin follow brief recoveri posit
growth clearli unexpect given manag optimist comment last
quarter dental final turn corner would stabil low-single-digit organ
growth weak attribut inventori destock north
american distribut channel though also modest declin europ japan
quarter result revenu tradit consum equip busi
declin said manag encourag fact north american sell-out
data posit quarter believ inventori adjust
channel complet meanwhil specialti consum busi
mid-single-digit solid perform across orthodont implant led nobel
biocar segment oper margin contract bp quarter driven
increment invest ahead pend separ bp foreign
exchang impact said manag project sequenti improv dental
oper margin
diagnost diagnost achiev solid organ revenu growth quarter
core oper margin declin bp due unfavor fx trend particularli
dental revenu mix
equip
thank strength china offset soft develop market along growth
immunoassay autom applic radiomet leica biosystem deliv
anoth quarter high-single-digit growth cepheid achiev double-digit growth
line manag expect sequenti acceler
outstand organ revenu growth mark best quarterli perform sinc
strength led water qualiti platform deliv double-digit
growth thank strength across water treatment analyt instrument
busi specif hach double-digit quarter driven china
thank local govern invest water qualiti improv addit
manag believ hach team strong commerci execut contribut
market share gain us europ across industri municip end market
meanwhil chemtreat organ growth acceler sequenti mid-single-digit led
demand metal mine food beverag market final trojan high-
single-digit driven share gain municip end market north america note
likelihood trojan may stolen market share xylem wedeco busi
player ultraviolet disinfect separ product id platform deliv
mid-single-digit organ growth quarter led high-single-digit videojet mark
consecut quarter least mid-single-digit top-lin growth
upcom catalyst point monitor
plan separ dental independ publicli trade compani
announc intend spin dental segment revenu stand-alone
publicly-trad compani tax-fre transact complet given
segment multipl year market challeng poor growth hard us see
move capitul especi time manag attent
invest dental turnaround said segment rel
stronger posit today expand gross margin bp sinc
consolid number opco three reduc manufactur back-
offic footprint past year manag primari rational separ
dental view flexibl organ inorgan invest
includ stand-alone compani recal argument led
manag success spin current group execut
presid dental amir aghdaei becom presid ceo spinco
coma cfo retir serv special advisor
cfo transit plan way announc current cfo coma
would pass cfo torch matt mcgrew current group cfo diagnost
dental effect januari big fan mr coma age capabl held
cfo posit year sinc april buy-sid sell-sid poll mr
coma perenni top-rank public compani cfo multi-industri sector
help drive four-fold increas market cap tenur although mr
coma agre stay advisor much intrigu
potenti next step might outsid separ known mr mcgrew
mani year previous vice-president investor relat serv busi line
financ leader group cfo sinc complet confid mr
mcgrew next cfo
acquir genom consum provid integr dna technolog roughli
billion complet acquisit privat held provid
reagents/consum genom applic significantli expand danah
presenc fast-grow genom market compani previous
manag stress
run dual-
track process
separ dental
intent sell
potenti buyer
goal sole spin
stand-alone public
compani similar
blueprint
modestli expos beckman life scienc busi estim purchas
price roughli billion impli rel full ebitda multipl
overal believ valuat reason given prevail multipl biotech
genom stock today term cash ep accret expect contribut
cent idt reagent use genom applic
molecular biolog qpcr next-gener sequenc synthet biolog gene edit
molecular diagnost primari function manufactur custom dna
rna oligonucleotid view match key characterist ideal
base e-commerc platform almost entir recurring/consum mix attract
margin said manag conced expect acquisit reach
double-digit join pall cepheid grow list larg
acquisit fallen short previous strict return threshold
expect achiev double-digit core revenu growth attract margin
compani averag expect gener million
revenu next month would account total mix
life scienc addit busi achiev mid-teen core revenu
compound-annual-growth-rate past three year manag expect maintain pace
futur importantli achiev attract gross margin vs
ebitda margin vs manag plan oper
stand-alone busi portfolio expect achiev meaning synergi
leverag life scienc platform intern scale idt geograph mix
us implement db expand profit time
balanc sheet fulli reload least billion addit capac
estim even compani complet billion acquisit april
estim still billion firepow feasibl deploy
next month net debt-to-ebitda current suggest healthi level
medium-term capac deal-mak primari criteria double-digit
small bolt-on deal larger acquisit key characterist
attract target includ fragment market secular growth driver high
barrier entri compani strong brand direct busi custom
intimaci recur revenu final manag emphas pull
back capit deploy plan even work separ dental tax-fre spin
next year
rel price-to-earnings trade midpoint target rang follow
fortiv spin juli believ achiev multipl expans beyond
histor valuat level given cyclic legaci industri busi
remov portfolio believ target rel premium rang vs
peer applic new portfolio current trade
premium group report ep cash ep believ stock
trade premium target group multipl impli price target
support sector perform rate current level
ev/ebitda premium higher qualiti ev/ebitda basi trade
estim repres rel premium multi-industri peer
group averag surpris premium group given outsiz
 a-driven amort premium price-to-earnings
note danah
funnel rel less
sensit rise interest
rate environ given
engin credit qualiti
share price trade premium weight averag price-to-earnings publicli
trade peer report ep cash ep believ
deserv premium reflect market leadership db toolkit
price assum after-tax cost capit beta annual sale growth
termin growth rate
compani report capit market estim
millionsmarjunsepdecmar-ajun-asep-adecmarjunsepdecmarjunsepdecseg revenueslif environment appli total revenu organ revenu sale gener incomelif appli expens oper interest expens incom intang per share per share per share earn per share outstand outstand analysi gross oper pre-tax net incom sale sell gener research tax new pension account corpor expens exhibit danah annual incom statement
compani report capit market estim
revenueslif appli revenu sale gener life appli expens oper income/expense- net interest intang per share earn per share per share earn per share outstand outstand analysi gross oper pre-tax net incom sale sell gener research tax asdiscontinu oper electr equip multi-industri
follow spin fortiv corp believ re-rat higher beyond
rel price-to-earnings rang within trade histor target
rang given divest cyclic legaci industri
busi believ trade high-end rang due
healthi outlook investor enthusiasm pend dental spin potenti
 catalyst premium target group multipl price-to-earnings
adjust ep cash ep impli valuat support
sector perform rate
risk rate price target
acquisit one acquisit compani multi-industri sector
alway risk overpay experienc integr difficulti major
deal given pricey pall cepheid acquisit multipl believ integr
stumbl would damag investor trust leadership
organ growth acquisition-focus busi model investor often hone
organ revenu growth metric perceiv miss often
disproportion effect stock earn
econom condit macro trend inflat currenc credit avail suppli
chain materi cost could caus result lower forecast
financi risk disrupt global credit market could caus sale
earn estim optimist
margin sinc gener among highest gross margin sector
degre execut risk would see shortfal profit
regulatori chang govern regul us intern could
neg impact compani especi elev
beneficiari increas regul water product mark
manag success oper histori execut legendari
db framework seen manag talent period poach
industri compani time exodu talent could affect oper
manufactur market profession medic industri commerci
product servic facil locat across countri compani oper
four segment life scienc diagnost dental environment appli solut
also oper differenti framework growth lean leadership tool
process known danah busi system across aspect oper includ
product develop qualiti control global sourc sale market danah
modestli headquart washington employ peopl global
